Dr. Clay Siegall is a trained and experienced researcher who concentrates on developing antibody-based therapies for managing cancer through the killing of cancerous cells. He is the CEO, chair of the executive board, and president of Seattle Genetics. He collaborated with a team of researchers and scientists to launch Seattle Genetics in 1998. In his capacity as the CEO, Dr. Clay conducts capital generation initiatives for the company. He manages the operations of the firm, and he has set many new trends in the biotechnology sector.
Dr. Clay gained experience in research and development of medications after working in several research institutions for decades. He holds a doctorate in Genetics, which allows him to understand the development stages of cancer and possible tactics for treating it. Dr. Clay chose to create Seattle Genetics to improve research on therapies and medications for treating cancer. He leverages his deep-rooted scientific knowledge to spearhead the development of best practices and reliable antibody therapies in the healthcare sector.
Addressing the unmet needs of cancer patients
Dr. Clay has guided Seattle Genetics towards fulfilling the unmet demands of cancer patients. The firm has launched a commercialized medication that got approval in 2011. It is now available in more than 64 nations. Seattle Genetics is carrying out trials to find out if ADCETRIS can fight other diseases other than cancer.
Dr. Clay Siegall joins Mirna Therapeutics
In 2013, Mirna Therapeutics welcomed a committed cancer research specialist, Dr. Clay, to its executive board. Headquartered in Texas, Mirna Therapeutics is an internationally renowned biotechnology-based firm that furthers cancer research, a specialty in which Dr. Clay has an unparalleled experience. Dr. Clay is a respected board member of prominent companies, such as Alder Biopharmaceuticals and Ultragenyx.
What is Seattle Genetics?
Seattle Genetics is an exceptional biotechnology-based firm whose mission is to create and commercialize novel, accredited antibody-based drugs for killing cancerous cells. The Washington-located biotechnology powerhouse is an important hub of antibody-drug conjugates (ADCs), advanced technology that revitalizes the targeting power of monoclonal antibodies to connect cancer-killing agents with cancerous cells. ADCs target only the cancer cells and spare the non-cancerous ones.